TScan Therapeutics, Inc.
TCRX
Positions held
Your positionsTCRX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $15.47M | Enterprise value | $6.20M | Trailing P/E | — | Forward P/E | -0.40 |
| PEG | — | Price / book | 0.22 | Beta | 1.14 | Dividend yield | 0.00% |
| Revenue growth | -65.8% | Earnings growth | — | Gross margin | 0.0% | Operating margin | -29.0% |
| Profit margin | 0.0% | ROE | -95.8% | ROA | -31.5% | Debt / equity | 1.32 |
| Current ratio | 3.37 | Free cash flow | -$79.92M | Analyst recommendation | hold | Mean target | $1.00 |
| 52w high | $2.57 | 52w low | $0.22 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $1.1M | $1.0M | $2.6M | $2.5M | $3.1M | — |
| Op margin | -2901.3% | -2967.3% | -929.4% | -1475.6% | -1256.6% | — |
| Net income | -$30.4M | -$28.7M | -$23.0M | -$35.7M | -$37.0M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$30.5M | -$29.1M | -$23.9M | -$37.1M | -$38.7M | — |
- Revenue +7% vs prior quarter ($1.1M vs $1.0M).
- Operating margin expanded to -2901.3%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $10.3M | $2.8M | $21.0M | $13.5M | — |
| Op margin | -1315.4% | -4787.7% | -444.0% | -492.3% | — |
| Net income | -$130M | -$127M | -$89.2M | -$66.2M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$136M | -$135M | -$93.5M | -$66.6M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-04 · Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
2026-09-02 · TScan Therapeutics Cuts Workforce by 75% and Shifts Focus to Solid Tumor Program
2026-09-02 · TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
2026-08-26 · Why Is Amgen (AMGN) Ending Its Crohn's Disease Research Partnership?
2026-08-12 · TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates
2026-08-12 · TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-06 · Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates
2026-07-31 · Cell and gene therapy manufacturers turn to specialist automation partners
Price (daily)
Full chart · RSI · MACD · patterns